CTNM (Contineum Therapeutics) FCF Margin % : 0.00% (As of Jun. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Contineum Therapeutics's Free Cash Flow for the three months ended in Jun. 2024 was $-8.62 Mil. Contineum Therapeutics's Revenue for the three months ended in Jun. 2024 was $0.00 Mil. Therefore, Contineum Therapeutics's FCF Margin % for the quarter that ended in Jun. 2024 was 0.00%.

As of today, Contineum Therapeutics's current FCF Yield % is -7.52%.

The historical rank and industry rank for Contineum Therapeutics's FCF Margin % or its related term are showing as below:

CTNM' s FCF Margin % Range Over the Past 10 Years
Min: -66.3 Med: 37.87 Max: 37.87
Current: -66.3

During the past 3 years, the highest FCF Margin % of Contineum Therapeutics was 37.87%. The lowest was -66.30%. And the median was 37.87%.

CTNM's FCF Margin % is ranked better than
59.15% of 1038 companies
in the Biotechnology industry
Industry Median: -141.315 vs CTNM: -66.30

Contineum Therapeutics FCF Margin % Historical Data

The historical data trend for Contineum Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics FCF Margin % Chart

Contineum Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

FCF Margin %

37.87

Contineum Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
FCF Margin %	Get a 7-Day Free Trial				81.29	-	-	-	-

Competitive Comparison of Contineum Therapeutics's FCF Margin %

For the Biotechnology subindustry, Contineum Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Contineum Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Contineum Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Contineum Therapeutics's FCF Margin % falls into.

Contineum Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Contineum Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	18.935	/	50
	=	37.87 %

Contineum Therapeutics's FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	-8.618	/	0
	=	%

Contineum Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Contineum Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121

Website

https://www.contineum-tx.com

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.